Chikungunya Fever – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Chikungunya Fever – Pipeline Review, H2 2019’, provides an overview of the Chikungunya Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chikungunya Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Chikungunya Fever

– The report reviews pipeline therapeutics for Chikungunya Fever by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Chikungunya Fever therapeutics and enlists all their major and minor projects

– The report assesses Chikungunya Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Chikungunya Fever”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chikungunya Fever

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chikungunya Fever pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Activirosomes Ltd

Bharat Biotech Ltd

Bow Therapeutics

Ciloa

Clayton Biotechnologies Inc

Emergent BioSolutions Inc

Ennaid Therapeutics LLC

Etubics Corp

Globavir Biosciences Inc

Hawaii Biotech Inc

HSRx Group

Immunomodulation Inc

Imophoron Ltd

Indian Immunologicals Ltd

Inovio Pharmaceuticals Inc

Integral Molecular Inc

Integrated BioTherapeutics Inc

Medigen Inc

Moderna Therapeutics Inc

Najit Technologies Inc

Pai Life Sciences Inc

Paradigm Biopharmaceuticals Ltd

Plant Bioscience Ltd

Precision Virologics Inc

Profectus BioSciences Inc

Quratis Inc

Riboscience LLC

Sementis Ltd

Shionogi & Co Ltd

Takeda Pharmaceutical Co Ltd

Themis Bioscience GmbH

Valneva SE

Vaxart Inc

VenatoRx Pharmaceuticals Inc”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Chikungunya Fever - Overview 5

Chikungunya Fever - Therapeutics Development 6

Chikungunya Fever - Therapeutics Assessment 14

Chikungunya Fever - Companies Involved in Therapeutics Development 22

Chikungunya Fever - Drug Profiles 31

Chikungunya Fever - Dormant Projects 84

Chikungunya Fever - Product Development Milestones 86

Appendix 98

List of Tables

“List of Tables

Number of Products under Development for Chikungunya Fever, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Chikungunya Fever – Pipeline by Activirosomes Ltd, H2 2019

Chikungunya Fever – Pipeline by Bharat Biotech Ltd, H2 2019

Chikungunya Fever – Pipeline by Bow Therapeutics, H2 2019

Chikungunya Fever – Pipeline by Ciloa, H2 2019

Chikungunya Fever – Pipeline by Clayton Biotechnologies Inc, H2 2019

Chikungunya Fever – Pipeline by Emergent BioSolutions Inc, H2 2019

Chikungunya Fever – Pipeline by Ennaid Therapeutics LLC, H2 2019

Chikungunya Fever – Pipeline by Etubics Corp, H2 2019

Chikungunya Fever – Pipeline by Globavir Biosciences Inc, H2 2019

Chikungunya Fever – Pipeline by Hawaii Biotech Inc, H2 2019

Chikungunya Fever – Pipeline by HSRx Group, H2 2019

Chikungunya Fever – Pipeline by Immunomodulation Inc, H2 2019

Chikungunya Fever – Pipeline by Imophoron Ltd, H2 2019

Chikungunya Fever – Pipeline by Indian Immunologicals Ltd, H2 2019

Chikungunya Fever – Pipeline by Inovio Pharmaceuticals Inc, H2 2019

Chikungunya Fever – Pipeline by Integral Molecular Inc, H2 2019

Chikungunya Fever – Pipeline by Integrated BioTherapeutics Inc, H2 2019

Chikungunya Fever – Pipeline by Medigen Inc, H2 2019

Chikungunya Fever – Pipeline by Moderna Therapeutics Inc, H2 2019

Chikungunya Fever – Pipeline by Najit Technologies Inc, H2 2019

Chikungunya Fever – Pipeline by Pai Life Sciences Inc, H2 2019

Chikungunya Fever – Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2019

Chikungunya Fever – Pipeline by Plant Bioscience Ltd, H2 2019

Chikungunya Fever – Pipeline by Precision Virologics Inc, H2 2019

Chikungunya Fever – Pipeline by Profectus BioSciences Inc, H2 2019

Chikungunya Fever – Pipeline by Quratis Inc, H2 2019

Chikungunya Fever – Pipeline by Riboscience LLC, H2 2019

Chikungunya Fever – Pipeline by Sementis Ltd, H2 2019

Chikungunya Fever – Pipeline by Shionogi & Co Ltd, H2 2019

Chikungunya Fever – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019

Chikungunya Fever – Pipeline by Themis Bioscience GmbH, H2 2019

Chikungunya Fever – Pipeline by Valneva SE, H2 2019

Chikungunya Fever – Pipeline by Vaxart Inc, H2 2019

Chikungunya Fever – Pipeline by VenatoRx Pharmaceuticals Inc, H2 2019

Chikungunya Fever – Dormant Projects, H2 2019

Chikungunya Fever – Dormant Projects, H2 2019 (Contd..1), H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports